Loading...
•
Jun 30, 2022
Allovir Q2 2022 Earnings Report
AlloVir reported financial results for the second quarter ended June 30, 2022.
Key Takeaways
AlloVir reported a net loss of $44.6 million, or $0.69 per share, for the quarter ended June 30, 2022. The company's cash, cash equivalents, and marketable securities totaled $172.7 million as of June 30, 2022, which, combined with proceeds from a registered direct offering, are expected to fund Phase 3 trials of posoleucel and global regulatory submissions.
Phase 3 study of posoleucel for the prevention of clinically significant infections continued to expand globally.
The European Medicines Agency confirmed orphan medicinal product designation granted to posoleucel.
New health economic and outcomes research data described the clinical and economic burden of multiple viral infections post allo-HCT.
Compassionate use case reports of ALVR109 administered to six immunocompromised patients with protracted COVID-19 infection were presented at ATC in June 2022.
Forward Guidance
AlloVir expects operating expenses to be in the range of $130 million to $145 million for fiscal year 2022, excluding non-cash stock-based compensation expense.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...